4.7 Article

Predictors of remitting, periodic, and persistent childhood asthma

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 125, 期 2, 页码 359-366

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2009.10.037

关键词

Remission; natural history; persistent asthma

资金

  1. National Center for Research Resources [NO1-HR-16044, NO1-HR-16045, NO1-HR-16046, NO1-HR-16047, NO1-HR-16048, NO1-HR-16049, NO1-HR-16050, NO1-HR-16051, NO1-HR-16052, M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]
  2. NHLBL
  3. AstraZeneca
  4. Aerocrine
  5. Genentech
  6. GSK
  7. Merck
  8. Novartis
  9. GlaxoWellcome
  10. Pfizer
  11. NIH/NHLBI
  12. NIH/NIAID
  13. GlaxoSmithKline

向作者/读者索取更多资源

Background: The course of mild to moderate persistent asthma in children is not clearly established. Objective: To determine the rate and predictors for remitting, periodic, and persistent asthma in adolescence. Methods: The Childhood Asthma Management Program (CAMP) was a 4.3-year randomized, double-masked, multicenter trial in children with mild to moderate persistent asthma that compared continuous therapy with either budesonide or nedocromil, each to placebo, followed by a 4-year observational follow-up period. Asthma activity during the observation period included remitting (no asthma activity in the last year), persistent (asthma activity in every quarter), and periodic asthma (neither remitting nor persistent). Results: Asthma was identified as remitting in 6%, periodic in 39%, and persistent in 55% of the 909 participants, with no effect noted from earlier anti-inflammatory treatment during the CAMP trial. Within all 3 asthma activity categories, improvements in airway hyperresponsiveness, eosinophilia, and asthma morbidity were observed over time. Features at entry into CAMP associated with remitting versus persistent asthma were lack of allergen sensitization and exposure to indoor allergens (odds ratio [OR], 3.23; P < .001), milder asthma (OR, 2.01; P = .03), older age (OR, 1.23; P = .01), less airway hyperresponsiveness (higher log methacholine FEV1 PC20 (OR, 1.39; P = .03), higher prebronchodilator FEV1 percent predicted (OR, 1.05; P = .02), and lower forced vital capacity percent predicted (OR, 0.96; P = .04). Conclusion: Remission of asthma in adolescence is infrequent and not affected by 4 years of anti-inflammatory controller therapy. Factors such as sensitization and exposure, low lung function, and airway greater hyperresponsiveness decrease the likelihood of remitting asthma. (J Allergy Clin Immunol 2010;125:359-66.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据